Cobimetinib hemifumarate

Overview

Cobimetinib hemifumarate is a novel selective MEK1 inhibitor, and the IC 50 value against MEK1 is 4.2 nM.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Obesity | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MEK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-13064A
• CAS No.: 1369665-02-0
• Molecular Formula: C21H21F3IN3O2.1/2C4H4O4
• Molecular Weight: 589.25
• Purity: 99.68%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (4.24 mM); Clear solution
• Availability: In-stock

Source

Original product source